
doi: 10.1586/eri.13.14
pmid: 23566148
Carbapenem-resistant Acinetobacter baumannii pose a significant threat to hospitalized patients, as therapeutic options are scarse. Alarmingly, rates of carbapenem-resistance in A. baumannii are on the rise and are slowly becoming a routine phenotype for this organism. This review focuses on infection control strategies for identification and control of A. baumannii, as well the available therapeutic options.
Acinetobacter baumannii, Colistin, Disease Management, Minocycline, Tigecycline, beta-Lactam Resistance, beta-Lactamases, Anti-Bacterial Agents, Disease Outbreaks, Aminoglycosides, Carbapenems, Epidemiological Monitoring, Humans, Acinetobacter Infections
Acinetobacter baumannii, Colistin, Disease Management, Minocycline, Tigecycline, beta-Lactam Resistance, beta-Lactamases, Anti-Bacterial Agents, Disease Outbreaks, Aminoglycosides, Carbapenems, Epidemiological Monitoring, Humans, Acinetobacter Infections
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 115 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
